BPX 101

Drug Profile

BPX 101

Alternative Names: AP-1903 activated BPX 101; BP-GMAX-CD1; BPX-101; Rimiducid activated BPX 101

Latest Information Update: 24 Sep 2015

Price : $50

At a glance

  • Originator Bellicum Pharmaceuticals
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 24 Sep 2015 Discontinued - Phase-I/II for Prostate cancer (Combination therapy, Hormone refractory) in USA (Intradermal)
  • 06 Oct 2014 ARIAD and Bellicum restructures license agreement for ARIAD's cell-signaling technology
  • 01 Mar 2012 Bellicum Pharmacueticals completes a phase I/II trial in Prostate cancer (hormone refractory; combination therapy) in USA (NCT00868595)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top